Market Place
Sourcing Support
Spero Therapeutics Announces Q3 2024 Operating Results & Update
14 Nov 2024 //
GLOBENEWSWIRE
Spero Therapeutics Q3 2024 Results & Updates on Nov 14
07 Nov 2024 //
GLOBENEWSWIRE
Spero speared by antibiotic flop, triggering 39% workforce cut
30 Oct 2024 //
FIERCE BIOTECH
Spero Therapeutics Announces SPR720 Phase 2a Interim Results
29 Oct 2024 //
GLOBENEWSWIRE
Spero Presents SPR719 Data Demonstrating Low Resistance at IDWeek
16 Oct 2024 //
GLOBENEWSWIRE
Spero Announces Publishes SPR720 Phase 1 Lung Data In AAC Journal
03 Oct 2024 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Spero Therapeutics Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
Spero Therapeutics To Report Q2 2024 Results On August 5, 2024
29 Jul 2024 //
GLOBENEWSWIRE
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
03 Jul 2024 //
GLOBENEWSWIRE
Spero Announces Nasdaq Employee Inducement Grant
03 Jun 2024 //
GLOBENEWSWIRE
Spero To Participate In Wainwright BioConnect Conference
16 May 2024 //
GLOBENEWSWIRE
Spero Announces Q1 2024 Operating Results, Business Update
15 May 2024 //
GLOBENEWSWIRE
Spero Q1 2024 Results, Business Update On May 15
08 May 2024 //
GLOBENEWSWIRE
Spero Therapeutics: Inducement Grants Under Nasdaq 5635(c)(4)
01 May 2024 //
GLOBENEWSWIRE
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results
13 Mar 2024 //
GLOBENEWSWIRE
Spero Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
Spero Therapeutics Announces Clearance of IND for SPR206
28 Feb 2024 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Cowen™s 44th Annual Healthcare Conference
26 Feb 2024 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2024 //
GLOBENEWSWIRE
Spero Therapeutics Provides Corporate Update and 2024 Outlook
05 Jan 2024 //
GLOBENEWSWIRE
Spero Announces First Patient, First Visit for Ph 3 Trial Evaluating Tebipenem
02 Jan 2024 //
GLOBENEWSWIRE
Spero Therapeutics Announces Third Quarter 2023 Operating Results
13 Nov 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Report Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer
01 Nov 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Upcoming November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Oct 2023 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2023 //
GLOBENEWSWIRE
Spero to Present at Cantor™s Global Healthcare 2023 Investor Conference
20 Sep 2023 //
GLOBENEWSWIRE
Spero to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
31 Aug 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Second Quarter 2023 Operating Results
10 Aug 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Agreement with FDA for Phase 3 of Tebipenem HBr
31 Jul 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
30 Jun 2023 //
GLOBENEWSWIRE
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
14 Jun 2023 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 May 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces First Quarter 2023 Operating Results
11 May 2023 //
GLOBENEWSWIRE
Spero Therapeutics to & Business Update & Report 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Upcoming Investor Conference
26 Apr 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Present Data at the 33rd European Congress
14 Apr 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
31 Mar 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces 4Q and Full Year 2022 Operating Results
30 Mar 2023 //
GLOBENEWSWIRE
Spero Reschedules Fourth Quarter and Full Year 2022 Earnings Release
13 Mar 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Report Fourth Quarter & Full Year 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Upcoming Investor Conferences
28 Feb 2023 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Feb 2023 //
GLOBENEWSWIRE
Spero Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2023 //
GLOBENEWSWIRE
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
22 Dec 2022 //
GLOBENEWSWIRE
Spero Therapeutics to Present at 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
Spero Therapeutics Announces 3Q 2022 Operating Results & Provides Business
14 Nov 2022 //
GLOBENEWSWIRE
Spero Therapeutics ends exclusive license pact with GSK for tebipenem HBr
10 Nov 2022 //
PHARMABIZ
Spero Announces Closing Exclusive License Agreement with GSK for Tebipenem HBr
08 Nov 2022 //
GLOBENEWSWIRE
Spero Therapeutics to Provide Business Update and Report 3Q 2022 Results
07 Nov 2022 //
GLOBENEWSWIRE
Spero Therapeutics to Present Data at IDWeek 2022
19 Oct 2022 //
GLOBENEWSWIRE
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous SPR720 Program
03 Oct 2022 //
GLOBENEWSWIRE
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA CMO
15 Sep 2022 //
GLOBENEWSWIRE
Spero Therapeutics to Present at Upcoming Investor Conference
07 Sep 2022 //
GLOBENEWSWIRE
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A
06 Sep 2022 //
GLOBENEWSWIRE
Spero Therapeutics Announces Q2 Operating Results and Provides Business Update
10 Aug 2022 //
GLOBENEWSWIRE
